Jak inhibitors are potent anti-inflammatory drugs that have the potential to dampen the hyperactive inflammatory response associated with severe COVID-19. We reviewed the clinical outcomes of 218 patients with COVID-19 hospitalized for severe pneumonia and treated with ruxolitinib through a compassionate use program. Data on the duration of treatment; outcomes at 4, 7, 14, and 28 days; oxygen support requirements; clinical status; and laboratory parameters were retrospectively collected. Overall, according to the physician evaluation, 66.5% of patients showed improvement at follow-up; of these, 83.5% showed improvement by day 7. Oxygen support status also showed improvement, and by day 7, 21.6% of patients were on ambient air, compared with 1.4% at baseline, which increased to 48.2% by day 28. Significant decreases in C-reactive protein and increases in the lymphocyte total count were already observed by day 4, which seemed to correlate with a positive outcome. At the end of the observation period, 87.2% of patients were alive. No unexpected safety findings were observed, and grade 3/4 adverse events were reported in 6.9% of patients.
【저자키워드】 COVID-19, SARS-CoV-2, Pneumonia, ruxolitinib, hyperactive inflammatory response, 【초록키워드】 Hospitalized, severe COVID-19, C-reactive protein, outcome, Clinical outcome, lymphocyte, adverse event, Patient, severe pneumonia, inhibitor, patients, compassionate use, Inflammatory response, Support, observation period, anti-inflammatory drug, oxygen support, positive, ambient, laboratory parameter, decrease, collected, reported, treated, Significant, increases in, baseline, patients with COVID-19, 【제목키워드】 inhibition, Italy, clinical, Program, Jak, experience, with COVID-19,